SCHEMBL6342147

SCHEMBL6342147

COC(=O)c1c(C(C)C)c(C(=O)O)cn1N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 3/20 0.32
HSD17B10 Q99714 2/20 0.32
HPGD P15428 1/20 0.32
KCNH2 Q12809 1/20 0.31
ALDH1A1 P00352 2/20 0.31
CFTR P13569 1/20 0.31
TSHR P16473 1/20 0.31
NR4A2 P43354 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NR1H2 P55055 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
DAPK3 O43293 1/20 0.30
JAK2 O60674 1/20 0.30
PRKD3 O94806 1/20 0.30
MAP4K4 O95819 1/20 0.30
ABL1 P00519 1/20 0.30
CSF1R P07333 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5596724 0.90 LMNA (0.38) LMNASMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL4050385 0.79 MEN1 (0.36) LMNAKDM4EHSD17B10ALDH1A1CFTR
Ethane SCHEMBL15559374 0.72 ABL1 (0.38) LMNAKDM4EHSD17B10HPGDALDH1A1
SCHEMBL6022285 0.72 KMT2A (0.39) LMNAKDM4EHSD17B10HPGDALDH1A1
SCHEMBL4050384 0.71 ALDH1A1 (0.39) LMNASMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL30590689 0.68 MAP3K5 (0.35) HPGDMEN1KMT2ADAPK3JAK2
SCHEMBL14451934 0.67 ATM (0.38) KDM4EHSD17B10HPGDALDH1A1CFTR
SCHEMBL6835627 0.65 KDM4E (0.38) KDM4EHSD17B10HPGDALDH1A1MEN1
SCHEMBL28554392 0.65 KDM4E (0.44) LMNAKDM4EHSD17B10HPGDALDH1A1
SCHEMBL21561527 0.64 ATM (0.35) LMNASMN1; SMN2KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234060-A1 Pyrrolotriazine kinase inhibitors BHIDE RAJEEV S 2005-10-20 US disclosed
US-6951859-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-04 US disclosed
US-20040063708-A1 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063708-A1 Pyrrolotriazine kinase inhibitors FGFR1, FLT1, FGFR2 LMNA 4591/4885SMN1; SMN2 4223/4885KDM4E 1969/4885
US-20050234060-A1 Pyrrolotriazine kinase inhibitors FGFR1, FLT1, FGFR2 LMNA 4591/4885SMN1; SMN2 4428/4885KDM4E 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.